Raymond James Financial Services Advisors, Inc. Xenon Pharmaceuticals Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 14, 2021	SELL	$13.65 - $21.31 $139,912 - $218,427	-10,250 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$9.49 - $16.04 $97,272 - $164,410	10,250 New	10,250 $158,000

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

Avoro Capital Advisors LLC New York, NY

5.67M
Shares

$217 Million
3.36% of portfolio
Driehaus Capital Management LLC Chicago, IL

4.6M
Shares

$176 Million
1.77% of portfolio
Wellington Management Group LLP Boston, MA

3.84M
Shares

$147 Million
0.03% of portfolio
Braidwell LP Stamford, CT

2.71M
Shares

$104 Million
3.02% of portfolio
Commodore Capital LP New York, NY

2.7M
Shares

$103 Million
9.03% of portfolio

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account